other material
confidence high
sentiment neutral
materiality 0.50
Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl
Larimar Therapeutics, Inc.
- Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).
- Series A preferred has no voting rights except as required by law and ranks pari passu with common on liquidation.
- Certificate of Amendment increased authorized Series A preferred from 250,000 to 500,000 shares.
- Exchange expected to close Jan 23, 2026, exempt from registration under Section 3(a)(9) of the Securities Act.
- Preferred shares are convertible into up to 2.5M common shares, subject to beneficial ownership limitations.